LoginSignup
Compass Pathways ADR logo

Compass Pathways ADR

Stock
Stock
ISIN: US20451W1018
Ticker: CMPS
US20451W1018
CMPS

Price

Price

Frequently asked questions

What is Compass Pathways ADR's market capitalization?

The market capitalization of Compass Pathways ADR is $304.47M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Compass Pathways ADR?

Compass Pathways ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.192. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Compass Pathways ADR's stock?

Currently, 9 analysts cover Compass Pathways ADR's stock, with a consensus target price of $40.38. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Compass Pathways ADR?

Compass Pathways ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$168.12M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Compass Pathways ADR?

Compass Pathways ADR has a free cash flow of -$105.21M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Compass Pathways ADR's stock?

The 5-year beta for Compass Pathways ADR is 2.27. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Compass Pathways ADR have, and what sector and industry does it belong to?

Compass Pathways ADR employs approximately 186 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Compass Pathways ADR's shares?

The free float of Compass Pathways ADR is 45.30M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $304.47M

5Y beta

 2.27

EPS (TTM)

 -$2.192

Free Float

 45.30M

EBITDA (TTM)

 -$168.12M

Free Cashflow (TTM)

 -$105.21M

Pricing

1D span
$4.339$4.586
52W span
$4.05$12.75

Analyst Ratings

The price target is $40.38 and the stock is covered by 9 analysts.

Buy

9

Hold

0

Sell

0

Information

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

186

Biotechnology & Drugs

Health Care

Identifier

ISIN

US20451W1018

Primary Ticker

CMPS

Knockouts

Join the conversation
Sign upLogin